01526 瑞慈醫療
按盘价 
0.870 +0.030 (+3.571%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | 6.309% | 6.262% | 7.905% | 6.389% | 4.151% |
| 股东资金回报率 (%) | 20.531% | 24.047% | 34.967% | 35.649% | 30.686% |
| 资本运用回报率 (%) | 9.970% | 10.367% | 14.714% | 12.051% | 7.244% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 43.189% | 39.931% | 41.752% | 39.040% | 35.871% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 38.778% | 35.453% | 35.211% | 32.525% | 30.636% |
| 税前边际利润率 (%) | 20.294% | 16.547% | 18.232% | 13.776% | 9.075% |
| 纯利率 (%) | 10.986% | 10.167% | 12.156% | 12.244% | 7.243% |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 0.975 X | 0.838 X | 0.664 X | 0.630 X | 0.710 X |
| 速动比率 (X) | 0.959 X | 0.819 X | 0.647 X | 0.612 X | 0.685 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 64.746% | 71.696% | 75.979% | 80.187% | 87.050% |
| 总债项 / 总资产比率 (%) | 41.245% | 47.345% | 48.872% | 50.331% | 60.476% |
| 净债项 / 总资产比率 (%) | 17.971% | 24.503% | 31.380% | 34.562% | 43.473% |
| 总债项 / 股东资金比率 (%) | 122.237% | 170.917% | 201.123% | 240.959% | 404.915% |
| 长期债项 / 股东资金比率 (%) | 82.409% | 110.382% | 120.218% | 148.637% | 247.844% |
| 净债项 / 股东资金比率 (%) | 53.259% | 88.455% | 129.140% | 165.466% | 291.075% |
| 净现金 / (债项) ($) | (8.77亿) | (11.90亿) | (14.55亿) | (15.78亿) | (19.72亿) |
| 每股净现金 / (债项) ($) | (0.551) | (0.749) | (0.915) | (0.993) | (1.240) |
| 总债项 / 资本运用比率 (%) | 65.317% | 80.205% | 91.669% | 95.257% | 109.464% |
| 利息盈利率 (X) | 6.664 X | 4.777 X | 5.292 X | 3.659 X | 2.466 X |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 7.510日 | 7.621日 | 7.970日 | 11.309日 | 10.753日 |
| 应收贸易帐周转率日数 (日) | 39.830日 | 38.911日 | 35.259日 | 48.059日 | 45.825日 |
| 应付贸易帐周转率日数 (日) | 20.744日 | 20.385日 | 20.440日 | 27.663日 | 25.671日 |
| 备注： | 实时报价更新时间为27/03/2026 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB 307,128 |
| 增长率 | 3.298% |
| 每股盈利/(亏损) | RMB 0.190 |
| 每股账面资产净值 (¥) | RMB 1.035 |